RxDoctor Payments Data

Sarah Koch, MD

Vascular Surgery · Tacoma, WANPI 1578859575

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,595 of the $3,946 with a category attached, or 65.8%. It is spread thinly across 22 manufacturers, the largest accounting for just 18.6%. That places this record below the midpoint for vascular surgery clinicians in WA, where the typical reported total is $4,221.

$3,946in general payments, 2019–2025

Across 75 payments — averaging $52.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$733
  • Cook Incorporated$669
  • Shockwave Medical, Inc$668
  • Inari Medical, Inc.$534
  • Cook Medical LLC$332
  • Johnson & Johnson$215
  • plus $796 from 16 others

What the payments were for

  • Speaking & faculty fees$100%
  • Travel & lodging$1,34134%
  • Food & beverage$2,59566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,946 in reported general payments places this provider in the 45th percentile of 111 vascular surgery providers in Washington.

See all vascular surgery providers in Washington

Medicare billing

Part B allowed, 2024
$154,415
Medicare patients
925
Services billed
1,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban19$16,722
ClopidogrelClopidogrel Bisulfate45$322
Atorvastatin Calcium50$290
Oxycodone Hcl31$136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$215$16,72219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 111 vascular surgery providers in Washington.

Other vascular surgery in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →